aluminum oxide has been researched along with canagliflozin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamada, K; Inagaki, N; Iwasaki, T; Mori-Anai, K; Nangaku, M; Sakata, Y; Sasaki, K | 1 |
1 other study(ies) available for aluminum oxide and canagliflozin
| Article | Year |
|---|---|
Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
Topics: Aged; Aluminum Oxide; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Product Surveillance, Postmarketing; Treatment Outcome | 2022 |